Spots Global Cancer Trial Database for Personalized DC Vaccine for Postoperative Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Personalized DC Vaccine for Postoperative Cancer

Official Title: Adjuvant Treatment in Cancer Patients With Neoantigen-primed DC Vaccine : a Single-arm, Open-label, Prospective Clinical Trial

Study ID: NCT04147078

Conditions

Gastric Cancer

Hepatocellular Carcinoma

Non-Small-Cell Lung Cancer

Colon Rectal Cancer

Interventions

DC vaccine subcutaneous administration

Study Description

Brief Summary: The study is aimed to the test efficacy and safety of neoantigen-primed dendritic cell (DC) cell vaccine therapy for postoperative locally advanced gastric cancer, hepatocellular carcinoma, lung cancer and colorectal cancer, and to explore the biomarkers related to efficacy and adverse event.

Detailed Description: Postoperative patients with pathological confirmed locally advanced gastric cancer, hepatocellular carcinoma, non-small cell lung cancer and colorectal cancer with standard adjuvant treatment are enrolled. This is a prospective exploratory trial. Patients' tumor tissues are subsequent to whole exosome sequencing and possible neoantigens are identified. DC is in vitro primed with synthesized peptides. Both adverse events and responses are recorded.